Literature DB >> 9667647

Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene.

K Ejeskär1, H Aburatani, J Abrahamsson, P Kogner, T Martinsson.   

Abstract

Neuroblastoma is a heterogeneous childhood tumour of the sympathetic nervous system, in which deletions of chromosomal region 1p and amplification of the MYCN oncogene correlate with aggressive tumour behaviour. However, the majority of neuroblastoma tumours show neither of these aberrations, indicating that other chromosomal regions may be involved in tumorigenesis. Here, we report findings of loss of heterozygosity (LOH) on chromosome 3. In our neuroblastoma material, nine of 59 (15.3%) tested tumours showed allelic loss of chromosome 3p markers. We found significant clinical and biological differences between tumours with the loss of one entire chromosome 3 vs tumours with partial loss in chromosome region 3p. All children with tumours with whole chromosome 3 loss are long-term survivors, whereas all children with tumours showing partial 3p LOH have died from tumour progression. A consensus region found to be deleted in all the tumours with 3p deletions was defined by markers D3S1286 and D3S1295, i.e. 3p25.3-p14.3, distal to the FHIT gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667647      PMCID: PMC2150348          DOI: 10.1038/bjc.1998.297

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Dup 3(q) syndrome and neuroblastoma.

Authors:  B Maier; J D Beck
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

Review 2.  The International Neuroblastoma Risk Groups (INRG): a preliminary report.

Authors:  R P Castleberry; J Pritchard; P Ambros; F Berthold; G M Brodeur; V Castel; S L Cohn; B De Bernardi; C Dicks-Mireaux; D Frappaz; G M Haase; M Haber; D R Jones; V V Joshi; M Kaneko; J T Kemshead; P Kogner; R E Lee; K K Matthay; J M Michon; R Monclair; B R Roald; R C Seeger; P J Shaw; J J Shuster
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

3.  International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.

Authors:  G M Brodeur; R C Seeger; A Barrett; F Berthold; R P Castleberry; G D'Angio; B De Bernardi; A E Evans; M Favrot; A I Freeman
Journal:  J Clin Oncol       Date:  1988-12       Impact factor: 44.544

4.  A first-generation physical map of the human genome.

Authors:  D Cohen; I Chumakov; J Weissenbach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

5.  Loss of heterozygosity for alleles on chromosomes 11q and 14q in neuroblastoma.

Authors:  E S Srivatsan; V Murali; R C Seeger
Journal:  Prog Clin Biol Res       Date:  1991

6.  Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma.

Authors:  T Martinsson; R M Sjöberg; F Hedborg; P Kogner
Journal:  Cancer Genet Cytogenet       Date:  1997-06

7.  Frequent loss of heterozygosity on chromosome 14q in neuroblastoma.

Authors:  T Suzuki; J Yokota; H Mugishima; I Okabe; M Ookuni; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

8.  Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification.

Authors:  C T Fong; N C Dracopoli; P S White; P T Merrill; R C Griffith; D E Housman; G M Brodeur
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

9.  Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin.

Authors:  J Roche; F Boldog; M Robinson; L Robinson; M Varella-Garcia; M Swanton; B Waggoner; R Fishel; W Franklin; R Gemmill; H Drabkin
Journal:  Oncogene       Date:  1996-03-21       Impact factor: 9.867

Review 10.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Authors:  G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

View more
  17 in total

1.  Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.

Authors:  Annalisa Pezzolo; Angela Rita Sementa; Margherita Lerone; Martina Morini; Marzia Ognibene; Raffaella Defferrari; Katia Mazzocco; Massimo Conte; Anna Rita Gigliotti; Alberto Garaventa; Vito Pistoia; Luigi Varesio
Journal:  Cancer Biol Ther       Date:  2017-04-12       Impact factor: 4.742

Review 2.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

Review 3.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

4.  Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

Authors:  John M Maris; George Hii; Craig A Gelfand; Shobha Varde; Peter S White; Eric Rappaport; Saul Surrey; Paolo Fortina
Journal:  Genome Res       Date:  2005-08       Impact factor: 9.043

5.  Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma.

Authors:  Angelo Agathanggelou; Ivan Bièche; Jalal Ahmed-Choudhury; Barbara Nicke; Reinhard Dammann; Shairaz Baksh; Boning Gao; John D Minna; Julian Downward; Eamonn R Maher; Farida Latif
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

Review 6.  Molecular and genetic bases of neuroblastoma.

Authors:  Takehiko Kamijo; Akira Nakagawara
Journal:  Int J Clin Oncol       Date:  2012-05-16       Impact factor: 3.402

7.  The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.

Authors:  Anna Djos; Tommy Martinsson; Per Kogner; Helena Carén
Journal:  Mol Cancer       Date:  2012-06-13       Impact factor: 27.401

8.  cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.

Authors:  Qing-Rong Chen; Sven Bilke; Jun S Wei; Craig C Whiteford; Nicola Cenacchi; Alexei L Krasnoselsky; Braden T Greer; Chang-Gue Son; Frank Westermann; Frank Berthold; Manfred Schwab; Daniel Catchpoole; Javed Khan
Journal:  BMC Genomics       Date:  2004-09-20       Impact factor: 3.969

9.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

10.  Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma.

Authors:  D Astuti; M Morris; C Krona; F Abel; D Gentle; T Martinsson; P Kogner; H P H Neumann; R Voutilainen; C Eng; P Rustin; F Latif; E R Maher
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.